Robert Hoffman, President and CEO at Kintara Therapeutics, a company dedicated to the development of unique anti-cancer therapeutics discusses VAL-083, a “first-in-class”, small-molecule chemotherapeutic with a novel mechanism of action that has demonstrated clinical activity against a range of cancers, including central nervous system (Glioblastoma Multiforme), ovarian and other solid tumors (e.g., non-small cell lung cancer, bladder cancer, head and neck) in U.S. clinical trials.
Robert E. Hoffman has served as our President and Chief Executive Officer since November 8, 2021, as our Chairman since June 2018, and as a director since April 2018. He has served as a member of Aslan Pharmaceuticals, Inc.’s Board of Directors since October 2018 and as a member of Antibe Therapeutics Inc.’s Board of Directors since November 2020 and as its chairman since May 2022. Mr. Hoffman served as Senior Vice President and Chief Financial Officer of Heron Therapeutics, Inc., a publicly-held pharmaceutical company from April 2017 to October 2020. Prior to joining Heron Therapeutics, Mr. Hoffman was CFO of various biotechnology companies including Arena Pharmaceuticals and AnaptyBio. Mr. Hoffman formerly served as a member of the Board of Directors of Kura Oncology, Aravive, and CombiMatrix Corporation. Mr. Hoffman served as a member of the Financial Accounting Standards Board’s Small Business Advisory Committee from 2010 until 2020. Mr. Hoffman holds a B.B.A. from St. Bonaventure University.